Daxxify is a botulinum toxin type A injectable stabilized with a peptide instead of albumin, with results that often last about six months, longer than Botox. Learn how it works, what it treats, the procedure, safety, cost, and how it compares.
Daxxify is a prescription botulinum toxin type A injectable, generic name daxibotulinumtoxinA-lanm, made by Revance. Like Botox, it relaxes muscles to soften frown lines, but it is stabilized with a peptide instead of human albumin, and its results often last about six months, longer than most other neurotoxins.
Daxxify is the newest of the major botulinum toxin injectables, and it arrived with a single, memorable claim: results that last about six months instead of the usual three to four. That longevity, made possible by a peptide-based formulation, is why so many people search for what Daxxify is and how it stacks up against Botox. This guide explains what Daxxify is made of, how it works, what it treats, what a treatment involves, how long it really lasts, its risks and costs, and how it compares with the alternatives, so you can decide whether it fits your goals.
FDA status: Daxxify is FDA-approved for moderate to severe glabellar (frown) lines in adults and for cervical dystonia. Use in other facial areas, such as the forehead and crow's feet, is off-label. This guide is educational and is not a substitute for personalized medical advice.
Daxxify is the brand name for daxibotulinumtoxinA-lanm, a prescription botulinum toxin type A injectable developed by Revance Therapeutics and approved by the U.S. Food and Drug Administration in September 2022. It belongs to the same family of neuromodulators as Botox, Dysport, Xeomin, and Jeuveau, all of which are purified forms of botulinum toxin type A that temporarily relax the small facial muscles responsible for expression lines. Injected in tiny, measured doses, Daxxify softens the frown lines that form between the eyebrows when you concentrate or squint.
What sets Daxxify apart is not how it works but how it is formulated and how long it lasts. Instead of the human serum albumin used to stabilize most other toxins, Daxxify uses a proprietary peptide, a short chain of amino acids, to hold the active molecule in place. That peptide formulation is thought to contribute to the product's signature feature: a duration of effect that commonly reaches about six months, noticeably longer than the three to four months typical of older neurotoxins. It also means Daxxify contains no human or animal blood-derived components, which matters to some patients for personal or religious reasons.
Daxxify is a prescription medication, which means it must be administered by or under the supervision of a licensed medical professional after an in-person evaluation. It is not a dermal filler and adds no volume; it works purely by quieting muscle movement. For people who like their results but dislike returning to the clinic every few months, that longer window is the main draw.
Every facial expression you make relies on nerves signaling muscles to contract. That signal is carried by a chemical messenger called acetylcholine, which nerve endings release to tell a muscle to fire. Botulinum toxin type A, the active ingredient in Daxxify, works by blocking the release of acetylcholine at the junction between nerve and muscle. When the message cannot get through, the treated muscle relaxes and stops pulling the overlying skin into a crease. Over the glabella, the area between the brows, this means the vertical frown lines known as the elevens gradually smooth out as the corrugator and procerus muscles soften.
The effect is local and selective: only the muscles that receive the injection are affected, and sensation, such as your ability to feel touch, is unchanged. The block is also temporary. Nerve endings slowly form new connections, and normal muscle movement returns over the following months. Daxxify's peptide stabilizer does not change this core mechanism, which is shared by all botulinum toxin products. What the peptide is designed to do is keep more of the active toxin intact and available at the injection site, which researchers believe helps explain the longer duration seen in clinical studies.
Because the mechanism targets movement rather than the skin surface, Daxxify works best on dynamic wrinkles, the lines that appear when you frown or squint. It works less well on deep static lines already etched into the skin at rest, which often need a dermal filler, resurfacing, or a combination approach. A patient whose glabellar creases are visible even with a completely relaxed face should expect softening rather than erasure from any neurotoxin.
Daxxify carries two FDA-approved indications. The first, cleared in 2022, is the temporary improvement of moderate to severe glabellar lines, the frown lines between the eyebrows, in adults. The second, approved in 2023, is cervical dystonia, a neurological condition that causes painful, involuntary neck muscle contractions. The cosmetic approval covers the glabella only; it does not formally extend to other areas of the face.
In practice, experienced injectors also use Daxxify off-label to treat forehead lines and crow's feet, the two other classic upper-face wrinkle zones, and occasionally for a lip flip or masseter treatment. Off-label does not mean unsafe or improper. It means the manufacturer has not sought or obtained FDA clearance for that specific use, so that area was not evaluated the same way in registration trials. Many off-label uses of botulinum toxin are well established and routine across aesthetic medicine.
The honest point for a patient is simply to know which category a treatment falls into and to ask the injector directly. Because Daxxify is newer than Botox, there is less published data on its performance in these off-label zones specifically, even though its underlying toxin behaves like the others. If you are considering Daxxify for the forehead, crow's feet, or another area, ask your provider what evidence supports it, whether a better-studied toxin might suit that area, and what duration to realistically expect there, since the roughly six-month figure comes from glabellar studies and may not carry over.
A Daxxify appointment looks much like any other neurotoxin visit and usually takes fifteen to thirty minutes. It begins with a consultation in which the injector reviews your medical history, medications, and goals, and examines how your frown muscles move. This screening matters: botulinum toxin is not appropriate for everyone, and a good provider will confirm you are a suitable candidate before proceeding. The treatment itself involves a series of small injections with a very fine needle into the targeted muscles. The FDA-approved glabellar regimen is 40 units total, given as five injections of 8 units each across the corrugator and procerus muscles, though your provider tailors the plan to your anatomy.
Most people describe the sensation as a quick pinch or sting at each point; numbing cream or ice can ease discomfort for those who are sensitive, though many patients do not need it. There is no anesthesia and no downtime in the usual sense. You can drive yourself home and return to most daily activities right away. Providers generally advise staying upright for a few hours and avoiding vigorous exercise, alcohol, and rubbing or massaging the treated area for the rest of the day, to reduce the small chance the toxin migrates from where it was placed.
Mild redness, swelling, or pinpoint bruising at the injection sites is common and fades quickly. You will not see results immediately: the muscle-relaxing effect builds over the following days, so the smoother look you are after emerges gradually rather than the moment you leave the chair. Most injectors schedule or offer a follow-up around the two-week mark to assess the settled result before deciding whether any refinement is warranted.
Daxxify does not work instantly. Softening typically begins within one to two days of treatment, which is a somewhat faster onset than the three to five days often quoted for Botox, and the full effect settles in over about two weeks. The headline advantage is longevity. In the pivotal SAKURA 1 and SAKURA 2 phase 3 trials, pooled data published in the Journal of the American Academy of Dermatology found that patients maintained none or mild glabellar line severity for a median of 24 weeks, roughly six months, after a single treatment. Published reviews note that some patients saw benefit persist as long as about nine months.
That is a meaningful step up from the three to four months most people get from other toxins, and it is the central reason a patient might choose Daxxify. Honesty matters here, though. A median of 24 weeks means half of patients experienced a shorter duration, and individual results vary with the dose used, the muscle being treated, a person's metabolism and muscle strength, and the injector's technique. Not everyone reaches the full six or nine months, and duration in off-label areas such as the forehead is far less thoroughly documented than in the glabella.
Results are not permanent by design. As the effect wears off, muscle movement and the frown lines return to their previous state; the toxin does not make lines worse. Maintaining the look requires repeat treatments, just fewer per year than with shorter-acting neurotoxins. No botulinum toxin offers a guaranteed outcome, and any provider promising a specific result or a specific number of months should be treated with caution.
Daxxify shares the safety profile of the botulinum toxin class, and like every product in it, its FDA label carries a boxed warning, the agency's most serious warning, about the distant spread of toxin effect. This warns that the toxin can, rarely, travel beyond the injection site and produce symptoms such as generalized muscle weakness, trouble swallowing, or difficulty breathing. These reactions are very uncommon at the low doses used for cosmetic frown-line treatment and are more associated with high therapeutic doses, but anyone who develops swallowing, speech, vision, or breathing problems after treatment should seek medical care immediately.
Far more common are mild, temporary effects at the injection site: bruising, redness, swelling, headache, or a feeling of tightness. The side effect people worry about most cosmetically is a drooping brow or eyelid, known as ptosis, or an uneven, overly frozen appearance. These generally result from the toxin affecting nearby muscles rather than from the drug itself being unsafe, are temporary, and resolve as the effect wears off. Choosing a skilled, licensed injector who understands facial anatomy is the single biggest factor in avoiding them.
Daxxify is not recommended during pregnancy or breastfeeding, or for people with certain neuromuscular disorders such as myasthenia gravis, Lambert-Eaton syndrome, or ALS, which can amplify toxin effects. It should be avoided if you have an infection at the planned injection site or a known allergy to any botulinum toxin product. Tell your provider about muscle relaxants, aminoglycoside antibiotics, and blood thinners, which can interact or increase bruising. One honest caveat specific to this product: because Daxxify is newer than Botox, its real-world safety record spans fewer years, even though its trial data and mechanism are consistent with the established class.
All five major neuromodulators are botulinum toxin type A and work by the same mechanism, so the practical differences come down to formulation, onset, duration, and cost rather than a fundamental difference in what they do. Daxxify's distinguishing traits are its peptide stabilizer, in place of the human serum albumin used by the others, and its longer typical duration. The table below summarizes the main points of comparison.
| Attribute | Daxxify | Botox | Dysport | Xeomin | Jeuveau |
|---|---|---|---|---|---|
| Active ingredient | daxibotulinumtoxinA-lanm | onabotulinumtoxinA | abobotulinumtoxinA | incobotulinumtoxinA | prabotulinumtoxinA-xvfs |
| Manufacturer | Revance | AbbVie (Allergan) | Galderma | Merz | Evolus |
| Stabilizer | Peptide (no albumin) | Human albumin | Human albumin, lactose | Human albumin, no complexing proteins | Human albumin |
| Typical duration | About 6 months (median 24 weeks in trials) | 3 to 4 months | 3 to 4 months | 3 to 4 months | 3 to 4 months |
| Onset | 1 to 2 days | 3 to 5 days | 2 to 3 days | 3 to 4 days | 2 to 3 days |
| FDA glabellar approval | 2022 | 2002 | 2009 | 2011 | 2019 |
| Approved cosmetic areas | Glabellar lines only | Glabellar, crow's feet, forehead | Glabellar lines | Glabellar lines | Glabellar lines |
| Relative cost per treatment | Highest | Moderate | Moderate | Often lowest | Moderate to lower |
No single toxin is best for everyone. Botox has by far the longest track record and the widest set of FDA-cleared cosmetic areas, which matters if you want treatment beyond the frown lines to be on-label. Dysport tends to diffuse a little more, which some injectors prefer for broad zones like the forehead. Xeomin is purified to remove complexing proteins, a formulation sometimes chosen for patients concerned about developing resistance. Jeuveau is positioned as a cosmetic-focused alternative to Botox. Daxxify's edge is duration, which suits people who want fewer visits, at the cost of a higher price and a shorter history.
Two practical cautions apply across the class. First, units are not interchangeable between brands: 20 units of one product is not clinically equivalent to 20 units of another, so dosing must be calculated per product and price comparisons based on unit counts are meaningless across brands. Second, the most important variable is not the label on the vial but the skill of the person holding the syringe. Injector technique drives how natural the result looks, how symmetric it is, and how long it holds, more than the brand choice does for most patients.
Daxxify generally costs more per treatment than Botox and the other established toxins, and pricing varies widely by provider, geographic region, injector credentials, and the number of units used. Clinics may quote Daxxify by the unit or as a flat fee for a treatment area such as the glabella. A single-area frown-line treatment commonly falls in the range of several hundred dollars, and full upper-face treatment can run higher. Because prices are set locally, change over time, and depend on your individual dose, any specific figure should be confirmed directly with the clinic at consultation rather than taken from an online estimate.
One important caveat concerns per-unit comparisons, which is what most people search for. Daxxify units are not equivalent to Botox units, so comparing the two brands purely on price per unit is misleading; a lower per-unit number does not necessarily mean a cheaper treatment overall, and a higher one does not necessarily mean a more expensive one. The more useful figures are the total cost per treatment and, given Daxxify's longer duration, the cost per month of results.
Because you may treat roughly twice a year with Daxxify instead of three or four times with a shorter-acting toxin, the higher sticker price can even out over a year for some patients. That math only works if your individual results actually last, which is not guaranteed. As a cosmetic treatment, Daxxify is not covered by insurance; cervical dystonia is a medical indication handled separately by a specialist. Ask for a full written quote, including planned unit count, before agreeing to treatment, and be wary of unusually cheap offers, which can signal over-dilution or an inexperienced injector.
Daxxify tends to suit people who already know they like the look of a relaxed frown line and want to maintain it with fewer appointments through the year. It can appeal to busy patients, to those who have found other toxins wear off too quickly, and to anyone who prefers a formulation free of human and animal blood-derived proteins. It is a less obvious first choice if you are brand new to neurotoxins and would rather test the waters with a shorter-acting product, since the longer duration means you live with the result, good or bad, for longer. It is not appropriate during pregnancy or breastfeeding, or for people with certain neuromuscular conditions, and only an in-person medical evaluation can confirm whether you are a candidate.
The most important decision is not the brand but the injector. Botulinum toxin results, and the risk of complications like brow droop, depend heavily on the provider's understanding of facial anatomy, dosing, and injection technique. Look for a licensed, experienced medical professional, a board-certified dermatologist, a plastic surgeon, or a qualified nurse injector or physician assistant working under proper medical supervision, who treats with neurotoxins regularly and will discuss FDA status, realistic duration, risks, and cost openly.
A useful consultation feels like a conversation about your anatomy and your goals, not a sales pitch. Good questions to ask: how many units do you recommend and why, is this area on-label or off-label for Daxxify, what should I expect at two weeks, what is your policy if the result is uneven, and would a different toxin suit my face better. A trustworthy provider will say plainly if another product would serve you better. When you are ready, compare qualified injectors near you and book a consultation.
Both are botulinum toxin type A and relax muscles the same way. Daxxify is stabilized with a peptide rather than human albumin, starts working slightly faster at one to two days, and lasts longer, about six months versus three to four for Botox. It is newer and usually costs more per treatment.
Clinics may price Daxxify per unit or per area, but Daxxify units are not equivalent to Botox units, so comparing brands by per-unit price is misleading. Focus on total treatment cost, often several hundred dollars for the frown area, and confirm the exact figure and unit count with your provider at consultation.
Yes. In the phase 3 SAKURA trials it reliably relaxed the frown muscles, with patients maintaining none or mild lines for a median of about six months. It is not magic, though: individual duration and results vary with dose, treated area, metabolism, and injector skill, and not everyone reaches the full six months.
Neither is clearly safer. Daxxify shares the botulinum toxin class safety profile and the same boxed warning about rare distant spread of toxin effect. Common side effects, such as bruising or temporary droop, are alike. Botox has a longer real-world record, while Daxxify's trial data is consistent with the class. Injector skill matters most.
South Korea produces several of its own botulinum toxin type A brands, including Nabota, sold in the United States as Jeuveau, plus products like Botulax and Meditoxin. They work by the same mechanism as Botox and Daxxify. Availability and regulatory approval differ by country, so options in Korea are not identical to those in the United States.